Showing results (161-170 of 259) with videos related to
Sort By:
Pageof 26
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 11, 2003
Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolitesA Fedier, M Schlamminger, V A Schwarz, et al.Cancer Research|March 14, 2001
P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatinX Lin, K Ramamurthi, M Mishima, et al.Seminars in Oncology|February 1, 1991
Intraperitoneal cisplatin-based chemotherapy for ovarian carcinomaS B Howell, S Kirmani, E F McClay, et al.Cancer Research|May 15, 1994
Cellular pharmacology of dichloro(ethylenediamine)platinum(II) in cisplatin-sensitive and resistant human ovarian carcinoma cellsA P Jekunen, D K Hom, J E Alcaraz, et al.Journal of the National Cancer Institute|October 23, 1997
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistanceM M de las Alas, S Aebi, D Fink, et al.Cancer Research|April 1, 1993
Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cellsE F McClay, K D Albright, J A Jones, et al.Surgical Oncology|January 1, 1993
Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposideP Lindnér, D D Heath, D R Shalinsky, et al.European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cellsE J Katz, J S Vick, K M Kling, et al.British Journal of Cancer|September 1, 1994
Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell linesE F McClay, K D Albright, J A Jones, et al.International Journal of Cancer|December 2, 1993
Tamoxifen modulation of cisplatin cytotoxicity in human malignanciesE F McClay, K D Albright, J A Jones, et al.Pageof 26